CDKN2A and cancer: In addition to the inhibition of TP53 by the ARF-MDM2-TP53 pathway, overexpression of NPM1 induces cellular growth and proliferation in a dose-dependent manner, suggesting NPM1 as a biomarker for cancer growth [40–42].